We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood-Based Proteomic Test to Enable Early Lung Cancer Detection

By LabMedica International staff writers
Posted on 05 Feb 2025

Lung cancer is the leading cause of cancer-related deaths globally. More...

More than 70% of cases are diagnosed at an advanced stage, but patients detected in the first stage have a 12-fold better five-year survival rate compared to those diagnosed at stage four, emphasizing the critical importance of early detection in improving outcomes. Now, a simple blood test to detect one of the deadliest cancers early aims to address this critical problem.

Oxford Cancer Analytics (OXcan; Oxford, UK) is focused on developing and globally commercializing innovative, minimally invasive liquid biopsy blood tests for early cancer detection. OXcan emerged from breakthroughs in combining advanced proteomics with tailored machine learning, transforming early cancer detection through blood tests. The company has created a patented approach, an advanced proteomics lab, and a platform dedicated to advancing the field of liquid biopsy. With a team of oncology innovation and machine learning experts, OXcan applies cutting-edge research techniques to analyze liquid biopsy data. In earlier studies, the company's machine learning models significantly improved detection rates for eight different cancer types by refining thousands of proteins into key biomarker signatures.

OXcan’s protein-based blood test identifies a molecular signature in patients at high risk for lung cancer. This simple, affordable, and precise blood test has the potential to facilitate earlier diagnoses and increase the number of individuals tested for lung cancer. The company has formed global partnerships to deploy the test on scalable platforms worldwide. OXcan is currently collaborating with over 20 healthcare centers across three continents, including pioneers in lung cancer screening, to refine and implement the technology. The company's diverse global biobank helps ensure more reliable biomarker identification across various populations, enhancing the test’s global applicability. Moreover, OXcan leverages advanced proteomics technology to detect a broader range of proteins, offering a more thorough understanding of the disease. The power of the OXcan proteomics biomarker discovery platform, coupled with the data generated, positions the company ahead of other liquid biopsy competitors, demonstrating superior performance in detecting early-stage lung cancer.

“Having developed blood-based proteomic tests for lung cancer for over two decades, I appreciate the difficulty of detecting cancers early through liquid biopsy,” said Dr. Heinrich Roder, SVP R&D at OXcan. “Convinced that OXcan’s unique approach can address this clinical need, I feel privileged to join the team. Together, our plan is to offer this novel technological approach to large markets worldwide to start a new era of early detection and improve patient outcomes.”

Related Links:
OXcan


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.